vs

Side-by-side financial comparison of Loews Corporation (L) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Loews Corporation is the larger business by last-quarter revenue ($827.0M vs $622.0M, roughly 1.3× Royalty Pharma plc). Loews Corporation runs the higher net margin — 48.6% vs 34.4%, a 14.2% gap on every dollar of revenue. On growth, Loews Corporation posted the faster year-over-year revenue change (4.8% vs 4.8%). Over the past eight quarters, Loews Corporation's revenue compounded faster (7.9% CAGR vs 4.6%).

Loews Corporation is a diversified US-based conglomerate that operates across multiple key industry segments through its subsidiaries. Its core business lines include property and casualty insurance, natural gas pipeline transportation, hospitality services, and upstream oil and gas exploration and production, primarily serving commercial, consumer and industrial clients across North American markets.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

L vs RPRX — Head-to-Head

Bigger by revenue
L
L
1.3× larger
L
$827.0M
$622.0M
RPRX
Growing faster (revenue YoY)
L
L
+0.0% gap
L
4.8%
4.8%
RPRX
Higher net margin
L
L
14.2% more per $
L
48.6%
34.4%
RPRX
Faster 2-yr revenue CAGR
L
L
Annualised
L
7.9%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
L
L
RPRX
RPRX
Revenue
$827.0M
$622.0M
Net Profit
$402.0M
$214.2M
Gross Margin
Operating Margin
65.4%
62.4%
Net Margin
48.6%
34.4%
Revenue YoY
4.8%
4.8%
Net Profit YoY
115.0%
2.9%
EPS (diluted)
$1.93
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
L
L
RPRX
RPRX
Q4 25
$827.0M
$622.0M
Q3 25
$732.0M
$609.3M
Q2 25
$769.0M
$578.7M
Q1 25
$846.0M
$568.2M
Q4 24
$789.0M
$593.6M
Q3 24
$683.0M
$564.7M
Q2 24
$711.0M
$537.3M
Q1 24
$710.0M
$568.0M
Net Profit
L
L
RPRX
RPRX
Q4 25
$402.0M
$214.2M
Q3 25
$504.0M
$288.2M
Q2 25
$391.0M
$30.2M
Q1 25
$370.0M
$238.3M
Q4 24
$187.0M
$208.2M
Q3 24
$401.0M
$544.0M
Q2 24
$369.0M
$102.0M
Q1 24
$457.0M
$4.8M
Operating Margin
L
L
RPRX
RPRX
Q4 25
65.4%
62.4%
Q3 25
94.1%
70.1%
Q2 25
70.1%
36.3%
Q1 25
60.8%
94.0%
Q4 24
23.8%
60.9%
Q3 24
80.5%
Q2 24
71.3%
50.2%
Q1 24
88.6%
-13.0%
Net Margin
L
L
RPRX
RPRX
Q4 25
48.6%
34.4%
Q3 25
68.9%
47.3%
Q2 25
50.8%
5.2%
Q1 25
43.7%
41.9%
Q4 24
23.7%
35.1%
Q3 24
58.7%
96.3%
Q2 24
51.9%
19.0%
Q1 24
64.4%
0.8%
EPS (diluted)
L
L
RPRX
RPRX
Q4 25
$1.93
$0.49
Q3 25
$2.43
$0.67
Q2 25
$1.87
$0.07
Q1 25
$1.74
$0.55
Q4 24
$0.87
$0.46
Q3 24
$1.82
$1.21
Q2 24
$1.67
$0.23
Q1 24
$2.05
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
L
L
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$6.0B
$618.7M
Total DebtLower is stronger
$8.4B
$9.0B
Stockholders' EquityBook value
$18.7B
$9.7B
Total Assets
$86.3B
$19.6B
Debt / EquityLower = less leverage
0.45×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
L
L
RPRX
RPRX
Q4 25
$6.0B
$618.7M
Q3 25
$5.4B
$938.9M
Q2 25
$4.5B
$631.9M
Q1 25
$4.4B
$1.1B
Q4 24
$4.6B
$929.0M
Q3 24
$5.2B
$950.1M
Q2 24
$4.9B
$1.8B
Q1 24
$5.4B
$843.0M
Total Debt
L
L
RPRX
RPRX
Q4 25
$8.4B
$9.0B
Q3 25
$8.4B
$8.9B
Q2 25
$7.9B
$8.0B
Q1 25
$8.4B
$7.6B
Q4 24
$8.9B
$7.6B
Q3 24
$8.8B
$7.6B
Q2 24
$8.6B
$7.6B
Q1 24
$8.4B
$6.1B
Stockholders' Equity
L
L
RPRX
RPRX
Q4 25
$18.7B
$9.7B
Q3 25
$18.3B
$9.6B
Q2 25
$17.5B
$9.5B
Q1 25
$17.2B
$9.8B
Q4 24
$17.1B
$10.3B
Q3 24
$17.4B
$10.3B
Q2 24
$16.4B
$9.8B
Q1 24
$16.2B
$9.9B
Total Assets
L
L
RPRX
RPRX
Q4 25
$86.3B
$19.6B
Q3 25
$85.9B
$19.3B
Q2 25
$84.7B
$18.3B
Q1 25
$83.1B
$17.6B
Q4 24
$81.9B
$18.2B
Q3 24
$83.6B
$18.0B
Q2 24
$81.1B
$17.7B
Q1 24
$80.9B
$16.1B
Debt / Equity
L
L
RPRX
RPRX
Q4 25
0.45×
0.92×
Q3 25
0.46×
0.93×
Q2 25
0.45×
0.84×
Q1 25
0.49×
0.78×
Q4 24
0.52×
0.74×
Q3 24
0.51×
0.74×
Q2 24
0.52×
0.78×
Q1 24
0.52×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
L
L
RPRX
RPRX
Operating Cash FlowLast quarter
$617.0M
$827.1M
Free Cash FlowOCF − Capex
$426.0M
FCF MarginFCF / Revenue
51.5%
Capex IntensityCapex / Revenue
23.1%
Cash ConversionOCF / Net Profit
1.53×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$2.7B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
L
L
RPRX
RPRX
Q4 25
$617.0M
$827.1M
Q3 25
$920.0M
$702.6M
Q2 25
$1.0B
$364.0M
Q1 25
$736.0M
$596.1M
Q4 24
$941.0M
$742.5M
Q3 24
$934.0M
$703.6M
Q2 24
$952.0M
$658.2M
Q1 24
$198.0M
$664.6M
Free Cash Flow
L
L
RPRX
RPRX
Q4 25
$426.0M
Q3 25
$764.0M
Q2 25
$872.0M
Q1 25
$638.0M
Q4 24
$767.0M
Q3 24
$794.0M
Q2 24
$793.0M
Q1 24
$39.0M
FCF Margin
L
L
RPRX
RPRX
Q4 25
51.5%
Q3 25
104.4%
Q2 25
113.4%
Q1 25
75.4%
Q4 24
97.2%
Q3 24
116.3%
Q2 24
111.5%
Q1 24
5.5%
Capex Intensity
L
L
RPRX
RPRX
Q4 25
23.1%
Q3 25
21.3%
Q2 25
17.4%
Q1 25
11.6%
Q4 24
22.1%
Q3 24
20.5%
Q2 24
22.4%
Q1 24
22.4%
Cash Conversion
L
L
RPRX
RPRX
Q4 25
1.53×
3.86×
Q3 25
1.83×
2.44×
Q2 25
2.57×
12.06×
Q1 25
1.99×
2.50×
Q4 24
5.03×
3.57×
Q3 24
2.33×
1.29×
Q2 24
2.58×
6.45×
Q1 24
0.43×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

L
L

Transportation And Storage Of Natural Gas And NG Ls And Ethane Supply And Transportation Services$601.0M73%
Lodging And Related Services$226.0M27%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons